The American Society of Echocardiography has issued a new consensus statement for interpreting and responding to results of carotid artery ultrasound. The guidelines set carotid artery wall thickness values greater than the 75th percentile as the threshold for aggressive treatment.
The American Society of Echocardiography has issued a new consensus statement for interpreting and responding to results of carotid artery ultrasound. The guidelines set carotid artery wall thickness values greater than the 75th percentile as the threshold for aggressive treatment.Carotid ultrasound has been used as a research tool for more than two decades and is increasingly turning into an established clinical practice. The ASE consensus statement provides standards for patient selection, scanning protocol, and interpretation to guide doctors on proper patient selection and management decisions. It provides specific guidance for detecting early atherosclerotic plaques and increased carotid intima-media thickness (CIMT). The document, however, recommends skipping imaging unless the results would be expected to alter therapy.These guidelines will help physicians feel more confident recommending aggressive preventive therapies if ultrasound reveals the walls of the carotid arteries are thicker than established cutoff points or percentiles for patients of similar age, sex, and race. They also provide recommendations for training and certification of sonographers and sonologists. The document sets the 75th percentile --which includes vessel wall thicknesses ranging from about 0.6 mm to 1.3 mm, as defined by eight large cohort studies-- as the threshold for aggressive treatment. Those who have CIMT equal or greater than that level for patients of similar age, sex, and race are considered to be at increased cardiovascular risk. There is a great interest in identifying patients who don't have symptoms of heart and blood vessel disease but who are at higher risk than they may appear. Having a safe, noninvasive approach for diagnosing early arterial disease and revealing potential heart disease will give doctors and patients the information they need to select the best treatment options, said Dr. James H. Stein, a cardiologist at the University of Wisconsin School of Medicine and Public Health.
Patients that may benefit from this test include those who:
Despite carotid ultrasound's proven value, the ASE is not recommending routine use of the procedure for all patients. The guidelines are designed to help physicians narrow their patient selection criteria to include those who will benefit most, said Stein, who is also the lead author of the ASE consensus statement.
"Carotid ultrasound to measure wall thickness and look for early plaques is most useful when other clinical information puts patients on the borderline between needing aggressive therapy and following a more standard approach," he said.The consensus panel recommended a comprehensive scan of all segments of both carotid arteries to look for the presence of plaques, as well as imaging of the far walls of each common carotid artery so CIMT can be measured. The presence of carotid plaque or increased CIMT is a marker of increased risk of heart attack, stroke, or death from cardiovascular disease.The consensus statement was also endorsed by the Society for Vascular Medicine. The full document is available at the ASE-sponsored website at www.seemyheart.org.For more information from the Diagnostic Imaging archives:
Screening tackles hidden cardiovascular disease in retired football pros
Contrast-enhanced ultrasound shows new marker for atherosclerosis
Carotid duplex ultrasound predicts cardiovascular complications
Heavily calcified carotid plaque reduces stroke risk
MRI or Ultrasound for Evaluating Pelvic Endometriosis?: Seven Takeaways from a New Literature Review
September 13th 2024While noting the strength of MRI for complete staging of disease and ultrasound’s ability to provide local disease characterization, the authors of a new literature review suggest the two modalities offer comparable results for diagnosing pelvic endometriosis.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
FDA Clears Controlled Contrast Delivery Method for Ultrasound Imaging of Fallopian Tubes
September 9th 2024Facilitating natural contrast delivery through an intrauterine catheter, FemChec can be utilized for ultrasound assessment of fallopian tubes and may provide diagnostic confirmation for an emerging non-surgical option for permanent birth control.
FDA Clears Emerging Cardiovascular Point-of-Care Ultrasound Platform
August 22nd 2024Combining four CAD modules for valvular pathologies with a variety of automated measurements, the AI-enabled AISAP Cardio ultrasound system reportedly facilitates up to a 90 percent accuracy rate in detecting common cardiac conditions.
Predicting DCIS Upgrade to Invasive Breast Cancer: Can Contrast-Enhanced Ultrasound Have an Impact?
August 21st 2024Adding two key findings from contrast-enhanced ultrasound to a predictive model of mammography, conventional ultrasound and clinicopathological findings led to a 86.1 percent AUROC for predicting the upgrading of ductal carcinoma in situ to invasive breast cancer, according to new research.